Trials / Completed
CompletedNCT03290612
Vitamin C to Reduce Morning Cardiovascular Risk
Chronotherapeutic Use of Vitamin C to Reduce Morning Cardiovascular Risk
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Oregon Health and Science University · Academic / Other
- Sex
- All
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study will test the efficacy of Vitamin C to counteract morning cardiovascular (CV) risk markers in a randomized, double blind, placebo controlled crossover pilot study. The participants will also perform morning typical behaviors such as arousal from sleep, change in posture (getting out of bed) and mild intensity physical activity; identical to the stressors encountered in everyday life. Primary dependent variables are markers of cardiovascular risk including vascular endothelial function and oxidative stress.
Detailed description
The investigators plan to test the efficacy of Vitamin C to counteract morning cardiovascular (CV) risk markers in a randomized, double blind, placebo controlled crossover pilot study. The participants will also perform morning typical behaviors such as arousal from sleep, change in posture (getting out of bed) and mild intensity physical activity; identical to the stressors encountered in everyday life. This pilot study is in healthy middle aged adults without a history of CV disease. Participants will spend two nights in an inpatient hospital suite at Hatfield Research Center. Upon awakening in the morning, they will either ingest Vitamin C or placebo in a randomized order. This will be followed by moderate intensity exercise, recovery, and discharge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Vitamin C | 1.5g Ascorbic Acid |
| OTHER | Placebo | Inactive placebo to mimic 1.5g ascorbic acid. |
Timeline
- Start date
- 2018-02-13
- Primary completion
- 2022-03-01
- Completion
- 2022-03-01
- First posted
- 2017-09-25
- Last updated
- 2023-03-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03290612. Inclusion in this directory is not an endorsement.